LifeVantage at Sidoti Conference: Strategic Growth Insights

LifeVantage Corporation (NASDAQ:LFVN) presented its strategic vision at the Sidoti March Small-Cap Virtual Conference on Thursday, 19 March 2026. The company highlighted its focus on nutrigenomics, a subscription-based revenue model, and international growth opportunities. While LifeVantage is confident in its future, challenges remain in integrating acquisitions and competing in the GLP-1 market.

• High gross margins at approximately 80%.

• Significant expenses are variable, including commissions and incentives.

• FY 2023: Approximately 5.5%.

• Long-term target: 12%.

• Annual revenue is around $200 million.

• Expected growth of 14% over fiscal 2024.

• U.S. is the largest market, with Japan contributing 11%.

• Remaining 18 countries account for the rest.

• Cash levels historically between $15-$20 million; recently at $10 million.

• $4 million spent on LoveBiome acquisition.

• $5 million revolving line of credit available.

• Renewed $75 million shelf registration.

• Internal investments prioritized.

• Dividend program started in 2022, with a yield of 3.9%.

• New $60 million share repurchase authorization.

• Protandim Nrf2: Reduces oxidative stress by 40% in 30 days.

• TrueScience Liquid Collagen: Increases collagen production by 100%.

• MindBody: Boosts GLP-1 production by over 200%, with average 11-pound weight loss.

• P84 (LoveBiome): Enhances production of 14 peptides in the gut.

• Completed in November, fully integrated.

• Partnership with Shopify for a new e-commerce platform.

• 50,000 active consultants and 70,000 active customers.

• International expansion in under-indexed regions.

• Continued product development and launches.

• Leveraging subscription-based model for growth.

• Competing in the GLP-1 market by positioning MindBody as a natural alternative.

• Driving growth through LoveBiome acquisition.

• Revenue has stabilized; focus remains on natural alternatives.

• Integration challenges resolved.

• Open to opportunities if they align with strategic goals.

• Active search for a successor; no announcement yet.

LifeVantage remains optimistic about its growth trajectory. For more details, refer to the full transcript below.

Anthony: Steve, the floor is yours. Awesome. Thank you, Anthony. Thank you everyone for joining us today. I hope you’ve had a good conference. It’s been. We’ve been quite busy. LifeVantage, just a quick overview of, you know, the size of the business. We are, as Anthony said, ticker symbol is LFVN. Our market cap is around $65 million. Revenue in the $200 million range and, you know, a profitable, debt-free company with cash. We are a pioneer really in a science referred to as nutrigenomics. It stands for, you know, it’s wholly science-backed, natural ingredients supplements. We focus on health and wellness opportunities.

Steve, CEO, LifeVantage: Our channel of distribution is through a direct selling channel, and we have consultants around the world. We do business in about 20 different countries. Our products are packaged in a way that lend themselves well to a subscription model. About 70% of our revenue is on a monthly subscription. Strong balance sheet with no debt. Revenue, like I said, in the $200 million range. We’ve got a very strong focus on in terms of returning returns to our shareholders, both in terms of our growth and profitability, but also from a capital allocation structure that we’ll go into more detail. We refer to ourselves as the activation company, again, in the health and wellness space.

When we talk about activate, it means both physical wellness, so inside and out, we’ll talk a little bit about our tagline of take it to make it. We provide a financial opportunity for our consultants to earn income by selling our product and by attracting other consultants to our business. We operate in the direct selling space. The graph on the left shows, you know, where the product categories in that space are. Our products fall within those two top categories of wellness and personal care. Geographically, the darker items there, or colors there, are countries that we are in. We participate in the top two categories as well as six of the ten largest countries in this space.

Here’s a view of our footprint, where almost 80% of our revenue comes from North America, 3% Europe, 18% in Asia. That pie chart on the right really shows the distribution of this industry. It’s about a $170 billion-dollar industry, and where the geographic footprint for the industry is. You can see just the comparison. We are over-indexed in the US and significantly under-indexed in the rest of the world, which presents a very great growth opportunity for us. Most recently, we acquired a company back in the September-October timeframe, company by the name of LoveBiome. I’ll talk a little bit more about the products that came with that company. First time LifeVantage has ever done an acquisition.

I’m happy to report that, as of November, the company is fully integrated. The consultant base that we acquired along with the products has been integrated and is operating under the LifeVantage compensation plan. We brought employees in that have been fully integrated and it’s early days, but it’s been a great acquisition for us so far. I mentioned briefly this activation approach and really what activation is to us, and it differs from supplementation. We activate our body’s natural ability to do what it was originally, you know, we were born to do, and probably was doing back when we were in our teens and our twenties, before we started eating maybe less healthy, not exercising as much, and just being exposed to environmental factors.

These pictures capture our four hero products. I’m gonna talk a little bit about each one of these. This tagline of take it to make it really ties into our view of what activation is. You take our products to have your body make what it was, again, naturally did. Our flagship product is a product and the product that the company was founded on, Protandim Nrf2. So you take this product to make antioxidants. This is a product that combats oxidative stress. We have over 30 peer-reviewed studies on it. Some of them are listed on this slide.

Perhaps one of the most notable ones is the National Institutes of Health did a study a few years ago, and it was the only nutraceutical product to have proven to reduce oxidative stress by 40% in 30 days. Oxidative stress is tied to a number of inflammatory diseases, and our product has been clinically proven to increase our body’s production of antioxidants. In fact, it might sound like an exaggeration, but it’s a million times more powerful than any supplement that you can take. Take Protandim Nrf2 to make antioxidants. Another one of our hero products that we introduced maybe 3 or 4 years ago is a liquid collagen product.

Similarly to our Protandim product, you’d take our TrueScience Liquid Collagen to make collagen and clinically proven to increase our body’s production of collagen by 100%. Well, I guess not our most recent, but a product that we launched about a year and a half ago, MindBody is a product focused on GLP-1 and weight management. You take our product to make GLP-1. This is a product that again is 100% natural. I’ll go on to this next slide. Here are some of the results of the two studies that we’ve done, clinical studies where it’s been proven to increase the production of GLP-1 in our bodies by over 200%.

Those studies also supported, you know, on average, a 11-pound weight loss over a 12-week period of time, 9% reduction in overall body fat, 24% reduction in visceral fat, which is really the bad fat. Perhaps that bullet point at the bottom of the first grouping, you know, 0% weight loss came from muscle loss, all from fat. Then there are also, you know, kind of qualitative type of benefits, reduced cravings. You know, we’re thrilled with this product in terms of being able to provide an alternatives to the synthetics that are out there in the market today.

A lot has happened in this space over the last 18 months, and we’re proud to be able to offer consumers an alternative to the drugs that are there. This is just an overview of the size of this market. It’s massive. It’s projected to continue to grow over the next several years, and we feel like we have a very compelling product to participate in this space. I mentioned the acquisition of LoveBiome. Their primary product, their hero product was a product referred to as P84. LoveBiome and their products were all focused around the gut and specifically the gut microbiome. This product has been proven to increase the production of 14 different peptides in our guts. So take P84 to make gut peptides.

Like I said, this acquisition was just completed in the November timeframe, and we’re seeing really some great results from this acquisition. Here’s just an overview. The gut health market is also growing tremendously as people, researchers understand more and more the importance around having a gut, a healthy gut as it relates to our overall health and wellness. Not only do we study individual products, but we also look at bundling our products together. We’ve done research on kind of the synergistic benefits of taking Protandim and liquid collagen together, and we see an amplification of those of those two products when taken together.

We do have a fairly robust, what we refer to as stacking, philosophy, where the science lends itself to be amplified through the production or through the use, the consumption of two or three of our products taken together. It obviously from a financial standpoint helps the average ARPA, the average revenue per account, increases as we bundle these products together. I mentioned about 70% of our revenue comes from subscriptions. We also have invested heavily over the last few years on how we compensate our independent contractors, our consultants. We developed or enhanced our compensation plan.

We call